Program Urges Increased Cancer Data Sharing
Stakeholders of Project Data Sphere authored a Sounding Board article in the New England Journal of Medicine urging the responsible sharing of cancer trial data with global researchers.
In an example of the continued push among industry, academia, government, and hospitals to share more clinical research data, stakeholders of Project Data Sphere, LLC (PDS), a non-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium, authored a Sounding Board article in this week’s New England Journal of Medicine urging the responsible sharing of cancer trial data with global researchers. Allowing researchers direct data access, the authors say, is critical to eliminating siloes and expanding discoveries and learnings in oncology R&D for the benefit of patients.
To that end, PDS has its own open-access cancer data platform, housing a free digital library of data. The platform, launched in 2014, allows researchers to download, share, integrate, and analyze patient data, while keeping patient anonymity intact. Presently, the platform includes 72 datasets resulting from nearly 42,000 patient lives, and PDS intends to expand the data and optimize the sharing of learned resources for trial participants. The platform can be found here: www.ProjectDataSphere.org
The CEO Roundtable on Cancer, comprised of top leaders from more than 30 U.S. companies, was founded by President Bush in 2001.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
